BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of “Moderate Buy” by Brokerages

by · The Markets Daily

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $378.4286.

A number of analysts recently issued reports on ONC shares. Citigroup lifted their target price on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 price target on shares of BeOne Medicines in a research report on Monday, November 17th. Zacks Research cut BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a research note on Monday, November 24th. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday, October 3rd.

Read Our Latest Analysis on BeOne Medicines

BeOne Medicines Stock Down 2.7%

BeOne Medicines stock opened at $340.38 on Friday. The company has a fifty day simple moving average of $326.85 and a 200 day simple moving average of $322.72. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. BeOne Medicines has a 1-year low of $196.45 and a 1-year high of $385.22. The company has a market cap of $37.33 billion, a P/E ratio of 667.41 and a beta of 0.47.

Insider Activity

In other BeOne Medicines news, CEO John Oyler sold 75,631 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $307.79, for a total transaction of $23,278,465.49. Following the transaction, the chief executive officer owned 24,369 shares of the company’s stock, valued at $7,500,534.51. The trade was a 75.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the company’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $340.90, for a total value of $895,544.30. The SEC filing for this sale provides additional information. Insiders have sold 128,610 shares of company stock valued at $41,114,068 over the last quarter. 6.62% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ONC. Legal & General Group Plc bought a new position in shares of BeOne Medicines during the second quarter worth approximately $13,857,000. Slow Capital Inc. bought a new stake in shares of BeOne Medicines in the second quarter valued at approximately $4,377,000. Virtus Investment Advisers LLC acquired a new stake in BeOne Medicines during the second quarter worth approximately $389,000. Baird Financial Group Inc. bought a new position in BeOne Medicines during the 2nd quarter worth $82,895,000. Finally, Public Employees Retirement System of Ohio bought a new position in BeOne Medicines during the 2nd quarter worth $3,491,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Featured Articles